251 related articles for article (PubMed ID: 27709352)
1. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
Reix N; Malina C; Chenard MP; Bellocq JP; Delpous S; Molière S; Sevrin A; Neuberger K; Tomasetto C; Mathelin C
Breast Cancer Res Treat; 2016 Nov; 160(2):249-259. PubMed ID: 27709352
[TBL] [Abstract][Full Text] [Related]
2. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer.
Lee SB; Lee JW; Yu JH; Ko BS; Kim HJ; Son BH; Gong G; Lee HJ; Kim SB; Jung KH; Ahn JH; Lee W; Sung J; Ahn SH
BMC Cancer; 2014 Dec; 14():929. PubMed ID: 25491647
[TBL] [Abstract][Full Text] [Related]
3. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
[TBL] [Abstract][Full Text] [Related]
4. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
[TBL] [Abstract][Full Text] [Related]
5. The extracellular domain of Her2 in serum as a biomarker of breast cancer.
Perrier A; Gligorov J; Lefèvre G; Boissan M
Lab Invest; 2018 Jun; 98(6):696-707. PubMed ID: 29491426
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.
Ludovini V; Gori S; Colozza M; Pistola L; Rulli E; Floriani I; Pacifico E; Tofanetti FR; Sidoni A; Basurto C; Rulli A; Crinò L
Ann Oncol; 2008 May; 19(5):883-90. PubMed ID: 18187484
[TBL] [Abstract][Full Text] [Related]
7. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.
Carney WP; Neumann R; Lipton A; Leitzel K; Ali S; Price CP
Clin Breast Cancer; 2004 Jun; 5(2):105-16. PubMed ID: 15245613
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
[TBL] [Abstract][Full Text] [Related]
10. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
[TBL] [Abstract][Full Text] [Related]
12. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
[TBL] [Abstract][Full Text] [Related]
13. Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer.
Tsai HP; Chen SC; Chien HT; Jan YY; Chao TC; Chen MF; Hsieh LL
World J Surg Oncol; 2012 Feb; 10():42. PubMed ID: 22339939
[TBL] [Abstract][Full Text] [Related]
14. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
Lennon S; Barton C; Banken L; Gianni L; Marty M; Baselga J; Leyland-Jones B
J Clin Oncol; 2009 Apr; 27(10):1685-93. PubMed ID: 19255335
[TBL] [Abstract][Full Text] [Related]
15. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
Li Y; Peng Z; Zhang X; Gong J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
[TBL] [Abstract][Full Text] [Related]
16. Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?
Badzek S; Kelovic VL; Plestina S; Humar I; Veir Z; Mihaljevic Z
Wien Klin Wochenschr; 2011 Dec; 123(23-24):726-31. PubMed ID: 22113445
[TBL] [Abstract][Full Text] [Related]
17. Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer.
Shi HZ; Wang YN; Huang XH; Zhang KC; Xi HQ; Cui JX; Liu GX; Liang WT; Wei B; Chen L
World J Gastroenterol; 2017 Mar; 23(10):1836-1842. PubMed ID: 28348489
[TBL] [Abstract][Full Text] [Related]
18. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
Fornier MN; Seidman AD; Schwartz MK; Ghani F; Thiel R; Norton L; Hudis C
Ann Oncol; 2005 Feb; 16(2):234-9. PubMed ID: 15668276
[TBL] [Abstract][Full Text] [Related]
19. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.
Kong Y; Dai S; Xie X; Xiao X; Lv N; Guo J; Li L; Jia W; Zhang Y; Liu W; Wei W; Xie X
J Cancer Res Clin Oncol; 2012 Feb; 138(2):275-84. PubMed ID: 22116318
[TBL] [Abstract][Full Text] [Related]
20. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
